A C C E P T E D M A N U S C R I P T Introduction
Multiple sclerosis (MS) is a demyelinating (degeneration of the myelin sheath) and axonal degenerating disease of the central nervous system (CNS). It is believed that autoimmunity plays a major role in pathogenesis MS, nevertheless its pathophysiological mechanism remains unclear. However, glial cells in the CNS, including microglia, astrocytes and oligodendrocytes, play important roles in various aspects of MS, for example, in the attraction of inflammatory cells, demyelination and remyelination (regeneration of the myelin sheath) (Clemente et al., 2013 , Domingues et al., 2016 . A model of experimental autoimmune encephalomyelitis (EAE), induced by immunization with myelin oligodendrocyte glycoprotein ) peptide, is the most commonly used animal model of MS. In this model, Bjelobaba et al. previously described the most accepted mechanism of EAE onset induced by MOG .
Immunization of MOG emulsified in complete Freund's adjuvant leads to the priming of myelin specific T cells (especially CD4 + T cells) in the secondary lymphoid organs. Activated T cells are differentiated into effector T cells and pass into the blood circulation. Then, effector T cells enter into CNS through the expression of adhesion molecules, cytokines, and chemokines leading to disintegration of blood-brain barrier (BBB). In the perivascular space or within CNS, effector T cells become reactivated after they recognize antigens on antigen-presenting cells such as microglia/macrophages and/or astrocytes. Effector T cells, macrophages and astrocytes amplify inflammatory response resulting in tissue damage and demyelination (Bjelobaba et al., 2018) . Arima et al. have shown that morphological changes are seen in the lumbar spinal cord in early phase of EAE according to autoreactive T cells infiltrating into the CNS via the fifth lumbar cord (Arima et al., 2012) . Generally, initial clinical symptoms of the EAE induced by MOG , started from tail as tail paralysis and then the paralysis progress ascending manner from limb to body bilaterally (Bittner et al., 2014) .
It has been reported that astrocytes are activated in the early stage after MOG peptide immunization and promote the infiltration of inflammatory cells by the production of chemokines (Karpus and Ransohoff, 1998, Calderon et al., 2006) . It has also been reported that astrocytes play a role in suppressing inflammatory cells by producing cytokines that inhibit invasion of these cells (Lalive et al., 2017) .
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Furthermore, activated astrocytes secrete extracellular matrix (ECM) proteins such as fibronectin and chondroitin sulfate proteoglycans (CSPGs), that inhibit remyelination (Correale and Farez, 2015) . Activated astrocytes have been reported to form scars (astrocytic scar) in a spinal cord injury model (Hara et al., 2017) , moreover astrocytic scars are evident in tissue from MS patients (Holley et al., 2003) . Thus, it is believed that reactive astrocytes in lesions and scar-forming astrocytes inhibit remyelination.
Fatty acid binding proteins (FABPs) are low molecular weight proteins (14-15 kDa) that serve as intracellular chaperones of long chain fatty acids, thereby regulating cellular lipid metabolism, signal transduction and gene expression (Owada, 2008) .
FABP7 (BLBP) is a well-known marker of neural stem cells and radial glia in the CNS.
In the embryonic brain, FABP7 is essential for the maintenance and proliferation of neural stem-progenitor cells and radial glia (Owada, 2008 , Liu et al., 2010 , expression of the FABP7 gene is considered to be downstream of Pax 6 and Notch signaling (Anthony et al., 2005 , Arai et al., 2005 . In the adult brain, we previously reported that FABP7 is expressed in astrocytes and oligodendrocyte precursor cells (OPC), and is involved in astrocytic proliferation in normal and stab-injured brain cerebral cortex (Sharifi et al., 2011) . Additionally, astrocyte-expressed FABP7 regulates dendritic morphology and the excitatory synaptic function of cortical neurons (Ebrahimi et al., 2016) . Furthermore, we also have reported that FABP7 controls lipid raft function in astrocytes through regulation of caveolin-1 expression, and that FABP7 deficiency results in altered response of astrocytes to external stimuli (Kagawa et al., 2015) . Based on the regulatory functions of FABP7 in astrocytes, it is highly possible that FABP7 exerts a critical role in various neurodegenerative diseases, nevertheless, its pathophysiological function in EAE remains elusive.
In the adult spinal cord, FABP7 is expressed in pial boundary glial fibrillary acidic protein (GFAP)-positive cells, and is increased in EAE lesions (Kipp et al., 2011) .
Although FABP7 may play roles in astrocyte activation during EAE, it remains unknown whether the functional involvement of FABP7 has an accelerative or suppressive effect on EAE pathophysiology. In this study, we aimed to clarify the functional involvement of FABP7 in the spinal cord during the pathogenesis of EAE.
We conclude that FABP7 in adult spinal cord astrocytes plays a pivotal role in the remyelination process by regulating fibronectin production.
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A C C E P T E D M A N U S C R I P T (Marusic et al., 2005 , Rao et al., 2015 , Choi et al., 2016 : 0, no detectable EAE symptoms; 1, tail paralysis/loss of tonicity; 2, abnormal gait; 3, hind limb paralysis; 4, hind limb and forelimb paralysis; and 5, moribund or dead; 0.5 gradations were assigned for intermediate scores.; Gradations of 0.5 were assigned for intermediate scores.
Immunohistochemistry, immunofluorescence staining and histochemistry
For immunohistochemistry and histochemistry, the mice were perfused intracardially with 4% paraformaldehyde (PFA) under anesthesia. The lumbar spinal cord (at the vertebral body level of L1 and L2) was sampled and post-fixed with fresh 4% PFA for overnight.
For paraffin embedded sections, lumbar spinal cords fixed with 4% PFA were dehydrated in gradual concentrations of ethanol, cleared in xylene, infiltrated, and then
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A C C E P T E D M A N U S C R I P T 7 embedded in paraffin. Tissue was cut into 4 m sections using a sliding microtome (Leica, Wetlar, Germany). Sections were de-paraffinized using xylene, and then hydrated with water. To detect de-myelinated lesions in the spinal cord, solochrome cyanine staining was performed according to a previous report (Kiernan, 2007) . To detect FABP7 in the spinal cord, de-paraffinized sections were stained with anti-FABP7
antibody (rabbit polyclonal antibody, 1:250) (Abdelwahab et al., 2003) using DAB method after blocking with 5% normal goat serum. Nuclei were stained using 4', 6-Diamidino-2-phenylindole (DAPI, 0.5 mg/ml, Thermo
Fisher Scientific) as a nuclear marker. Slides were cover-slipped using Fluoromount (Diagnostic Biosystems, CA, US).
The number of CD4 + T cells in a lumbar spinal cord section was counted using ImageJ software.
Measurement of fibronectin positive area in spinal cord sections
For quantitative analysis of the fibronectin-positive area in lumbar spinal cord sections (% fibronectin area), the ratio of fibronectin-positive to spinal cord parenchyma area inside the glia limitans, which was formed by GFAP-positive cells, was measured using
image analysis software (BZ-II Analyzer, KEYENCE, Osaka, Japan).
Western blotting
For Western blotting, raw lumbar spinal cord tissue was extracted from mice under anesthesia and stored in -80℃ until total protein extraction was performed. Isolated total protein was dissolved in lysis buffer (100 mmol/L Tris-HCl [pH6.8], 2% sodium dodecyl sulfate, 20% glycerol) and protein concentration was measured using the bicinchoninic acid (BCA) assay. Western blot analysis was performed as described previously (Kagawa et al., 2015) .
Primary astrocyte culture
Primary astrocytes were prepared from cerebral cortices of 0-to 1-day-old WT and FABP7-KO mice as described with slight modification (Kagawa et al., 2015) . In brief, w/v of EDTA (Sigma-Aldrich, Japan) and seeded into appropriate plates and dishes and grown 2-3 days until confluent. the purity of astrocyte was confirmed to be >95% by GFAP immuno-staining. Primary cultured astrocytes for both genotypes were isolated, passaged, and analyzed at the same time to minimized bias. When astrocytes reached to confluence, astrocytes were treated with/without TGF- (10 ng/mL, Biolegend) for 3 hrs. After 3hrs, total RNA was isolated from astrocytes using RNA easy micro kit (QIAGEN).
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Statistical analysis
All data are expressed as mean ± SEM. Statistical comparisons were performed using the Student's t-test, P < 0.05 was considered to be statistically significant.
Results
FABP7 expression in adult spinal cord during EAE
Initially, FABP7 expression was confirmed in normal adult lumbar spinal cord. FABP7
was highly expressed by small size cells located on the surface of the white matter (WM), around the central canal and in the dorsal gray matter (GM) (Fig. 1A , D, G, J) as previously reported (Kipp et al., 2011) . Double immunofluorescent histochemistry revealed that FABP7 was primarily localized in GFAP + cells, namely, astrocytes (Fig.   1C , F, I, L). As a negative control for FABP7 immunostainings, it was confirmed that all FABP7 + cells were absent in the spinal cord of FABP7-KO mice (data not shown).
Next, the distribution and the expression levels of FABP7 in the spinal cord was examined at 9 dpi (before onset of clinical symptom), at 15 dpi (peak of clinical symptoms), and at 21 dpi (late phase). Immunohistochemistry revealed a decreased number of FABP7 + GFAP + astrocytes in the lumbar spinal cord at 9 dpi compared with control ( Fig. 2A, B , E, F). At 15 dpi (peak of clinical symptoms), the number of FABP7 + GFAP + astrocytes was markedly increased throughout the spinal cord, especially in the WM compared with control ( Fig. 2C, G) . In addition, FABP7 expression in the dorsal and ventral GM astrocytes was also increased compared to
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A C C E P T E D M A N U S C R I P T 10 control (Fig. 2I, J, M, N) , although FABP7 the expression in ventral GM was faint in normal lumbar spinal cord. Increased expression of FABP7 was also observed around the central canal (Fig. 2Q, R) . At 21 dpi (late phase), FABP7 expression in WM-astrocytes remained higher relative to control (Fig. 2D, H) ; however, the expression levels of FABP7 in the GM were almost the same as control (Fig. 2K , L, O, P, S and T). When the distribution pattern of FABP7 + cells was compared with solochrome cyanine staining in the adjacent section of spinal cord, strong FABP7 was observed especially in the demyelinated region indicated by the absence of solochrome cyanine staining in WM (Fig.2U, V) . Consistent with the results of immunohistochemistry, in Western blotting, FABP7 expression levels were transiently decreased in the spinal cord at 9 dpi and markedly increased at 21 dpi compared with control ( Fig 2W) . Collectively, FABP7 was primarily expressed in WM-astrocytes in the lumbar spinal cord, and the expression of FABP7 increased in the demyelinated region of the WM after the onset of EAE.
Alterations in EAE clinical score in FABP7 KO mice
The degree of clinical symptoms of EAE in FABP7-KO and WT mice was compared using clinical scores. In WT mice, the first clinical signs (tip of tail was limp) were observed at day 9 dpi, and onset rate reached 100% at 13 dpi (Fig. 3A) . In FABP7-KO mice, the first clinical signs were observed at 8 dpi, and the onset rate reached 100% at 10 dpi (Fig. 3A) . The average time when the clinical score reached the peak was at 12 dpi and at 15 dpi in FABP7-KO and in WT mice, respectively (Fig 3B) . Moreover, the onset of clinical signs and the time to reach at the peak were both earlier in FABP7-KO than in WT mice (Fig. 3A, B) . There was no significant difference in peak clinical score between FABP7-KO (at day 12, score: 2.81 ± 0.23) and WT mice (day 15, score: 3.0 ± 0.28) (Fig. 3B) . In both mice genotypes, the clinical score decreased somewhat after the peak, however, it is interesting to note that FABP7-KO mice exhibited significantly lower clinical scores compared with WT mice from 15 dpi to 21 dpi (Fig. 3B) . At 21 dpi, the clinical score in WT mice was 2.29 ± 0.24 and 1.6 ± 0.19 in FABP7-KO mice.
Early induction of inflammation in FABP7-KO spinal cord
Demyelinated lesions in white matter at 10 dpi were observed in both WT and
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11 FABP7-KO spinal cord (Fig. 4A, B) . Furthermore, GFAP expression was higher around the lesions of white matter in WT and FABP7-KO spinal cord (Fig. 4C, D) compared to in intact white matter of control WT and FABP7-KO spinal cord (Fig. 4E, F) respectively. Since FABP7-KO mice had early onset of clinical symptoms rather than WT mice, we hypothesized that invasion of inflammatory cells in the spinal cord through BBB and initiation of inflammation in spinal cord may occur earlier in FABP7-KO mice than WT mice. The number of CD4 + cells infiltrated into lumbar spinal cord showed an increasing trend in FABP7-KO mice compared to WT mice, although there was no statistically significant difference ( Fig. 4G-I) . Furthermore, mRNA expression levels of IL-17 and TNF-, which are important inflammatory cytokines to induce demyelination, were higher in FABP7-KO lumbar spinal cord at 10 dpi than in WT lumbar spinal cord (Fig. 4J ). Both cytokines were rarely detected in intact spinal cord (data not shown). These results suggested that FABP7 in astrocyte may have a role to protect from the invasion of inflammatory cells into CNS and induction of demyelination.
Decreased fibronectin-positive area in the spinal cord of FABP7-KO EAE mice
Given the correlation with such differences in clinical score, the demyelinated area in the lumbar spinal cord was less apparent at 21 dpi in FABP7-KO mice compared with WT mice (Fig. 5A, B) . Highly GFAP expressing cells distributed in demyelinated area in both WT and FABP7-KO mice (Fig. 5C, D) . There is a possibility that amelioration of clinical symptoms during the late phase in FABP7-KO mice was associated with altered the process of remyelination. Fibronectin is one of the ECM proteins produced by activated astrocytes, up-regulated in MS lesions, and is known to inhibit oligodendrocyte differentiation and remyelination (van Horssen et al., 2006 , Stoffels et al., 2013 .
In normal lumbar spinal cord of mice of both genotypes, fibronectin was barely detected (data not shown). In the EAE model, fibronectin was increased in the lesion area where myelin basic protein immunoreactivity was decreased (data not shown) and considered to be the demyelinated region, and cells that highly expressed GFAP were present in the immediate vicinity of the fibronectin-positive region (Fig. 5E, F) . In immunohistochemistry at 21 dpi, the fibronectin-positive area was less discerned in the ACCEPTED MANUSCRIPT
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12 spinal cord parenchyma of FABP7-KO compared with WT mice (Fig. 5G, H ).
Quantitative analysis of % fibronectin positive area was 1.95 ± 0.21% in WT versus 1.36 ± 0.25% in FABP7-KO mice (p<0.05) (Fig. 5I) . Furthermore, mRNA expression of fibronectin 1 (Fn1) in primary culture astrocyte after treatment with/without TGF- was examined by qPCR. Although there was no significant difference in Fn1 expression between in FABP7-KO and WT-astrocytes without TGF- treatment, Fn1 expression was significantly lower in FABP-KO astrocytes compared with WT after TGF- treatment (Fig. 5J) . These results suggest that FABP7 in activated astrocytes may up-regulate the production of fibronectin in the demyelinated region of the spinal cord, and exerts inhibitory effects on the remyelination process.
Discussion
In this study, we demonstrated that FABP7 in adult mouse spinal cord was primarily expressed in astrocytes in the WM. Expression of FABP7 was low before the development of EAE symptoms, but became high after onset, and was particularly increased in reactive astrocytes in the demyelinated region of the WM. The onset of EAE clinical symptoms and the time to reach the peak were observed earlier in FABP7-KO mice compared with WT mice, while the symptoms improved in FABP7-KO mice rather than in WT mice in the late phase of EAE. Fibronectin, which has been suggested to prevent remyelination, was less distributed in the spinal cord of FABP7-KO mice in the late phase of EAE. Collectively, FABP7 may be involved in the regulation of fibronectin production through the modification of astrocyte activation and may inhibit remyelination.
Improvement of symptoms in the late stages of EAE was observed in FABP7-KO mice rather than in WT mice, although there was no difference in clinical score between two groups at the peak. Therefore, we hypothesized that FABP7 in astrocytes may inhibit remyelination by oligodendrocytes. Reactive and scar-forming astrocytes produce fibronectin, which inhibits the differentiation and myelination of oligodendrocytes (Siskova et al., 2009 , Stoffels et al., 2013 . In addition to fibronectin, other types of ECM proteins, such as CSPGs and the glycosaminoglycan hyaluronan are also produced by activated astrocytes in the damaged area of spinal cord and have the
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Furthermore, endothelin-1 and fibroblast growth factor-2 are also secreted by reactive astrocytes in demyelinated lesions, and these molecules are known to prevent remyelination (Goddard et al., 1999 , Hammond et al., 2014 . It has been reported that transforming growth factor (TGF- enhances the production of fibronectin via SMAD and/or MAPKs signaling by activated astrocytes (Tatomir et al., 2018) . We revealed that FABP7 deficient astrocytes impaired the expression of fibronectin after TGF- treatment compared to WT astrocytes. The TGF- receptor expression and SMAD and
MAPKs signaling activation should be examined. Other research groups have demonstrated that fibronectin expression is increased in cultured astrocytes after lipopolysaccharide (LPS) stimulation (Stoffels et al., 2013) . Recently, we reported that FABP7 controls lipid raft function through the regulation of caveolin-1 expression, and involved in the response of astrocytes to external stimuli. In FABP7-deficient astrocytes, LPS stimulated activation of signal transduction such as MAPKs was impaired compared with WT astrocytes (Kagawa et al., 2015) . In the EAE model, it was suggested that astrocytes with high expression of FABP7 in demyelinated regions may exhibit enhanced responses to external stimuli, including TGF-, eventually up-regulating fibronectin production. It is, therefore, necessary to investigate the involvement of FABP7 in the mechanism of fibronectin production. We did not actually observe the process of remyelination or OPC differentiation in this study, so further investigation is necessary.
In this study, the onset of EAE symptoms in FABP7-KO mice occurred earlier than in WT mice, and mRNA expression of inflammatory cytokines (IL-17 and TNF-a) in lumbar spinal cord of FABP7-KO mice were higher than of WT mice at EAE early phase. IL-17 and TNF- are important cytokines to induce demyelination, and mainly produced by Th17 (CD4+) cells and monocytes /macrophages including microglia respectively. We also demonstrated that astrocytic FABP7 expression was transiently downregulated throughout spinal cord at 9 dpi. The significance of such changes in FABP7 expression during the early phase of EAE remains unclear. However, one possibility is that FABP7 may modulate the function of blood-brain barrier (BBB), where astrocytes play a key maintenance role in its integrity (Abbott et al., 2006) . It has
A C C E P T E D M A N U S C R I P T 14 been reported that loss of astrocytic end-feet around small blood vessels represents an early event in lesion development linked to BBB disruption in EAE (Correale and Farez, 2015) . It is also known that activated CD4-positive T cells infiltrate the CNS during EAE, induce CNS inflammation, and promote demyelination (Constantinescu et al., 2011) . Therefore, the early disruption of BBB due to astrocytic FABP7 deficiency may enhance the infiltration of activated T cells into the CNS, and lead to the early development of EAE in FABP7-KO mice.
The majority of astrocytes are post-mitotic at physiological conditions, and highly active proliferation is usually associated with astrogliosis, (e.g., induced by spinal cord injury and EAE (Nash et al., 2011 , Lundgaard et al., 2014 . Astrocyte proliferation following injury may be important for scar formation (Bardehle et al., 2013) . Our group has reported that proliferation of reactive astrocytes after stab injury is decreased in FABP7-KO mice compared with WT mice (Sharifi et al., 2011) , we have also demonstrated that FABP7 regulates OPC proliferation (Sharifi et al., 2013) .
Furthermore, it has been reported that the expression of FABP7 is associated with the proliferation of glioma cells (Tian et al., 2018) . Therefore, results of the present study suggest that increased expression of FABP7 in reactive astrocytes in EAE lesions may modulate astrocyte proliferation and scar formation. We examined the proliferation of astrocytes by immuno-fluorescent staining for Ki67 and GFAP in spinal cord at 10, 15
and 21 dpi (data not shown). Ki67 + astrocytes were rarely seen in around lesions at 10 dpi whereas observed around lesions at 15 and 21 dpi. But, there was no significant difference in the number of Ki67 + astrocytes between WT and FABP7-KO mice at each time point. However, 15 and 21 dpi might not be the peak phase of astrocyte proliferation. Further detailed time course studies are needed to clarify this issue.
FABP7 was expressed primarily in astrocytes in the normal state, and a pathological state of spinal cord WM in this study. FABP7 expression was markedly enhanced during the remyelination period in the mouse model of EAE. It is known that astrocyte activity can be affected by the intracellular lipid milieu (Iglesias et al., 2017 , van Deijk et al., 2017 , thus, it is likely that FABP7 modulates astrocyte reactivity during EAE pathology through its involvement in lipid metabolism. Further studies are warranted to clarify the cellular mechanism of how FABP7 is involved in astrocytic activation in EAE pathology, which in turn may provide a molecular basis for expression levels were significantly decreased at 9 dpi, and increased at 21 dpi compared with control. However, FABP7-KO mice exhibited significantly lower clinical score compared with WT mice from 15 dpi to 21 dpi. *P < 0.05 
A C C E P T E D M A N U S C R I P T 22 Highlights -FABP7 was increased in astrocytes at demyelinated region after onset of EAE.
-The onset of clinical signs of EAE was earlier in FABP7-KO mice than in WT.
-FABP7-KO mice induced early onset of inflammation in spinal cord in EAE.
-Chronic symptoms of EAE was more improved in FABP7-KO mice compared with WT.
-Fibronectin expression was decreased in FABP7-KO spinal cord at late phase of EAE.
Figure 1 
